New imaging agent could light up depression, anxiety, and heart injury

NCT ID NCT07685860

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests a radioactive tracer called 18F-AIPF-1026 that binds to monoamine oxidase A (MAO-A), an enzyme linked to depression, anxiety, and heart injury. About 200 adults with these conditions will receive a single injection of the tracer and then undergo PET/CT or MRI scans. The goal is to see how well the tracer highlights affected tissues, potentially improving diagnosis and monitoring of these diseases.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
18F-AIPF-1026 (a radioactive tracer for PET/CT imaging)
What this could lead to
If successful, this imaging method could help doctors detect and monitor MAO-A-related diseases like depression, anxiety, and heart injury more accurately.
What could go wrong
This is an early diagnostic study, not a treatment trial. The tracer may not clearly distinguish disease from normal variation, and results may not change patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANXIETY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of University of Science and Technology of China

    RECRUITING

    Hefei, Anhui, 230000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tianjin Medical University General Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300052, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.